Novartis’ Leqvio cuts LDL levels by 50% over three years: #ESC23

Paul Schloesser

Associate Editor

Novartis said that 78.4% of patients in a Phase III met a pre-specified low-density lipoprotein cholesterol target after taking the siRNA cholesterol drug Leqvio for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis’ Leqvio cuts LDL levels by 50% over three years: #ESC23

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­var­tis’ Leqvio cuts LDL lev­els by 50% over three years: #ESC23

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis’ Leqvio cuts LDL levels by 50% over three years: #ESC23